Vigafyde (Vigabatrin) Patent Expiration, LOE Window & CMS Spending

Vigafyde (Vigabatrin) by Pyros: FDA Orange Book LOE 2043-06-08, 8 AB generics, $1.7M 2024 CMS Part D & Medicaid spend, and $3,235 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPyros
FDA Application & PathwayN217684 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2043-06-08
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$1.7M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$1.7M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($3,235 intro WAC)